Trial · NCT02048722
Results by group95
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 95
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) at 4 Months | Treatment (Regorafenib) | 52.17 | 95% Confidence Interval 35.28 to 77.16 | percentage of patients alive | |
| Progression-Free Survival (PFS) at 3 and 6 Months | Treatment (Regorafenib) | 3 months | 56.52 | 95% Confidence Interval 39.5 to 80.89 | percentage patients alive |
| Progression-Free Survival (PFS) at 3 and 6 Months | Treatment (Regorafenib) | 6 months | 47.83 | 95% Confidence Interval 31.21 to 73.29 | percentage patients alive |
| Median Progression-free Survival (PFS) | Treatment (Regorafenib) | 5.49 | 95% Confidence Interval 1.84 to 9.53 | months | |
| Overall Survival | Treatment (Regorafenib) | 14.06 | 95% Confidence Interval 9.76 to 22.24 | months | |
| Response Rate | Treatment (Regorafenib) | Complete Response | 2 | participants | |
| Response Rate | Treatment (Regorafenib) | Partial Response | 2 | participants | |
| Rate of Tumor Control | Treatment (Regorafenib) | Complete Response | 2 | patients | |
| Rate of Tumor Control | Treatment (Regorafenib) | Partial Response | 2 | patients | |
| Rate of Tumor Control | Treatment (Regorafenib) | Stable Disease | 9 | patients | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Blood and lymphatic system disorders / Grade 1 | 5 | Participants | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Blood and lymphatic system disorders / Grade 2 | 3 | Participants | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Blood and lymphatic system disorders / Grade 3 | 3 | Participants | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Blood and lymphatic system disorders / Grade 4 | 0 | Participants | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Blood and lymphatic system disorders / Number of patients who didn't experience any grade | 20 | Participants | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Endocrine disorders / Grade 1 | 1 | Participants | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Endocrine disorders / Grade 2 | 0 | Participants | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Endocrine disorders / Grade 3 | 0 | Participants | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Endocrine disorders / Grade 4 | 0 | Participants | |
| Number of Grade 1, 2, 3, 4, and 5 Related Adverse Events Observed During Study Treatment (Defined by CTCAE v 4.0) | Treatment (Regorafenib) | Endocrine disorders / Number of patients who didn't experience any grade | 30 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02048722/results